Compare · A vs DHR
A vs DHR
Side-by-side comparison of Agilent Technologies Inc. (A) and Danaher Corporation (DHR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Industrials sector. A focuses on Biotechnology: Laboratory Analytical Instruments, while DHR focuses on Industrial Machinery/Components.
- DHR is the larger of the two at $165.55B, about 3.3x A ($49.89B).
- DHR has been more active in the news (18 items in the past 4 weeks vs 6 for A).
- Both have 25 recent analyst ratings on file.
- Company
- Agilent Technologies Inc.
- Danaher Corporation
- Price
- -
- -
- Market cap
- $49.89B
- $165.55B
- 1M return
- -
- +5.44%
- 1Y return
- -
- +7.19%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 1999
- News (4w)
- 6
- 18
- Recent ratings
- 25
- 25
Agilent Technologies Inc.
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate readers; laboratory software, information management, and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression profiling, as well as sequencing target enrichment, genetic data management, and interpretation support software; and equipment to produce synthesized oligonucleotide. It also offers immunohistochemistry, in situ hybridization, and hematoxylin and eosin staining and special staining; instruments, consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. It has collaboration agreement with SGS AXYS. The company was incorporated in 1999 and is headquartered in Santa Clara, California.
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Latest A
- Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme
- Agilent Completes Acquisition of Proscia
- Agilent Launches 5987A MSD with GC Assist for Faster, Smarter GC/MS Workflows
- Agilent to Announce Fourth-Quarter Fiscal Year 2026 Financial Results on Nov. 23
- Agilent and University of Chicago Launch Center of Excellence for Energy Materials Research
- Deutsche Bank initiated coverage on Agilent with a new price target
- Agilent to Acquire Proscia, Advancing AI-Enabled Digital Pathology and Scientific Intelligence
- Agilent Introduces the NovoStation Sample Preparation System for Automated Flow Cytometry Workflows
- Agilent Introduces Gen5 AI Cell Identification Module for BioTek Automated Cell Imagers
- SEC Form EFFECT filed by Agilent Technologies Inc.
Latest DHR
- Executive Vice President Milosevich Gregory M sold $484,302 worth of shares (2,100 units at $230.62), decreasing direct ownership by 9% to 22,367 units (SEC Form 4)
- Executive Vice President Mcgrew Matthew exercised 17,385 shares at a strike of $88.24 and sold $4,097,452 worth of shares (17,385 units at $235.69) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Danaher Corporation
- Why the Next Edge in Antibody Discovery May Be What Labs Remember
- Integrated DNA Technologies and Aldevron Launch New mRNA Solutions to Simplify Base and Prime Editing
- Director Dewan Feroz was granted 144 phantom shares (SEC Form 4)
- Director Zerhouni Elias A. was granted 199 phantom shares (SEC Form 4)
- Director Filler Linda was granted 15 phantom shares (SEC Form 4)
- Director Stevens Raymond C was granted 153 phantom shares (SEC Form 4)
- Director List Teri was granted 13 phantom shares (SEC Form 4)